Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Jun;43(6):3519-3522.
doi: 10.1007/s10072-022-06054-3. Epub 2022 Apr 9.

COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors

Antonio Tanzilli  1 , Andrea Pace  2 , Gennaro Ciliberto  3 , Antonia Marina La Malfa  4 , Valentina Buonomo  2 , Dario Benincasa  2 , Annamaria Biscu  2 , Edvina Galiè  2 , Veronica Villani  2
Affiliations
Observational Study

COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors

Antonio Tanzilli et al. Neurol Sci. 2022 Jun.

Abstract

Background: The BNT162b2 vaccine conferred 95% protection against COVID-19 in people aged 16 years or older.

Objective: The aim of this observational study was to evaluate safety and efficacy of vaccine in patients affected by primary brain tumor (PBT).

Methods: We proposed COVID-19 vaccine to all patients affected by PBT followed by Neuroncology Unit of National Cancer Institute Regina Elena.

Results: 102 patients received the first dose, 100 the second, and 73 patients received the booster dose. After first dose, we observed one patient with fever and severe fatigue, while after the second one, we recorded adverse events in ten patients. No correlation was observed between adverse events and comorbidities.

Conclusions: The COVID-19 vaccine is safe and well tolerated in PBT patients.

Keywords: Brain tumors; COVID-19; Efficacy; Safety; Vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436. doi: 10.1038/s41586-020-2521-4. - DOI - PMC - PubMed
    1. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918. doi: 10.1016/S0140-6736(20)31187-9. - DOI - PMC - PubMed
    1. Martín-Moro F, Marquet J, Piris M, Michael BM, Sáez AJ, Corona M, Jiménez C, Astibia B, García I, Rodríguez E, García-Hoz C, Fortún-Abete J, Herrera P, López-Jiménez J (2020) Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol 190(1):e16–e20. 10.1111/bjh.16801 - PMC - PubMed
    1. Abdul-Jawad S, Baù L, Alaguthurai T, et al. Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients. Cancer Cell. 2021;39:257–75.e6. doi: 10.1016/j.ccell.2021.01.001. - DOI - PMC - PubMed
    1. Laing AG, Lorenc A, Molino Del, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020;26:1623–1635.7. doi: 10.1038/s41591-020-1038-6. - DOI - PubMed

Publication types